PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

World’s first clinical trials of COVID-19 vaccine combination

In a bid to combat future mutations of COVID-19, a joint research programme will begin in February 2021 to assess the immunogenicity and safety of the combined usage of two vaccines, Sputnik V and Oxford/AstraZeneca in clinical trials.

The Ministry of Healthcare of Republic of Azerbaijan has granted an approval to conduct clinical trials of the combined use of the Sputnik V and Oxford/AstraZeneca COVID-19 vaccines in Azerbaijan. Previously, the Gamaleya National Center, RDIF, AstraZeneca and R-Pharm signed an agreement to cooperate on COVID-19 vaccine development, which was announced in December 2020.

The world’s first clinical trial program to asses vaccines combination will be conducted in line with clinical trials protocol registered on December 24, 2020 and will take place in several countries, enrolling 100 adults aged 18 years and older.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) said: “We need to join our international efforts and use the most advanced solutions to defeat the coronavirus. A publication in the leading peer-reviewed medical journal, The Lancet, showed Sputnik V to be 91.6% efficacious. It is only one of three vaccines in the world with efficacy over 90%. We are ready to develop cooperation with other manufacturers to increase the number of affordable and effective drugs. The partnership for the clinical study of the combination of the COVID-19 vaccine AstraZeneca with the adenoviral vector Ad26 of the Sputnik V vaccine was the first and very important example of such cooperation in the world.”

Alexey Repik, the R-Pharm Chairman of the Board, noted: “R-Pharm has been actively working with the Republic of Azerbaijan for several years, we opened a modern production facility here in 2019, later in 2020 we registered two drugs from our anti-Covid portfolio: Artlegia and Coronavir. This pilot study is vital for developing of a new approach to the prevention of COVID-19, moreover the leading scientific and clinical centers of Azerbaijan will be able to make their own important contribution in this direction.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026